An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Clinical trial NCT00552396 · COMPLETED
Trial details
- NCT number
- NCT00552396
- Sponsor
- Innate Pharma
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-05-01
- Primary completion
- 2011-01-01
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.